EU's CHMP OKs Major New Uses for Hemlibra, Praluent, Forxiga – And More
Executive Summary
Several major products have been recommended for wider indications in the EU, including Roche’s hemophilia drug Hemlibra, Sanofi’s Praluent in atherosclerotic disease, and AstraZeneca’s Forxiga for type 1 diabetes.
You may also be interested in...
European CHMP Opinions And MAA Updates
This is a monthly update of recommendations from the European Medicines Agency's Committee for Medicinal Products for Human Use on the authorization of new medicines in the European Union, and updates on EU marketing authorization changes recommended by the CHMP.
New Products Soar And Old Stand Their Ground As Roche Heads Off Biosimilar Threat
New products helped Roche to 7% sales growth in 2018 but the outlook for 2019 is lower as the biosimilar headwinds start to blow from the US.
AZ Sees A Future For Forxiga In Type 1 Diabetes
The EMA is looking at a marketing authorization variation for the type 2 diabetes blockbuster SGLT-2 inhibitor for use as an oral adjunct treatment to insulin in adults with type 1. Observers will be interested to see what stance the agency takes on the slightly higher number of diabetic ketoacidosis events seen in trials supporting the submission.